MA42946A - Sels et formes solides d'un antibiotique de type monobactame - Google Patents
Sels et formes solides d'un antibiotique de type monobactameInfo
- Publication number
- MA42946A MA42946A MA42946A MA42946A MA42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A MA 42946 A MA42946 A MA 42946A
- Authority
- MA
- Morocco
- Prior art keywords
- salts
- solid forms
- monobactam antibiotic
- oxo
- amino
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 2
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 title 1
- 229960003644 aztreonam Drugs 0.000 title 1
- 230000003115 biocidal effect Effects 0.000 title 1
- FWTGYTRQUBRVDW-NRABZWKMSA-N NC=1SC=C(N1)/C(/C(N[C@@H]1C(N([C@@H]1CN1C(OCC1)=O)S(=O)(=O)O)=O)=O)=N/OC1(CC1)C(=O)O Chemical compound NC=1SC=C(N1)/C(/C(N[C@@H]1C(N([C@@H]1CN1C(OCC1)=O)S(=O)(=O)O)=O)=O)=N/OC1(CC1)C(=O)O FWTGYTRQUBRVDW-NRABZWKMSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La fourniture de nouvelles formes solides, des sels et des polymorphes d'acide 1-(((z)-(1-(2-aminothiazol-4-yl)2-oxo-2-(((3s,4r)-2-oxo-4-((2-oxooxazolidine-3-yl)méthyl)-1-sulfoazetidin-3-yl)amino)éthylidène)amino)oxy)-cyclopropanecarboxylique (désigné ici en tant que composé x), des compositions pharmaceutiques les contenant et des procédés pour leur fabrication et leur utilisation en thérapie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222430P | 2015-09-23 | 2015-09-23 | |
| PCT/CN2016/099482 WO2017050218A1 (fr) | 2015-09-23 | 2016-09-20 | Sels et formes solides d'antibiotique monobactame |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42946A true MA42946A (fr) | 2018-08-01 |
| MA42946B1 MA42946B1 (fr) | 2020-10-28 |
Family
ID=58385723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42946A MA42946B1 (fr) | 2015-09-23 | 2016-09-20 | Sels et formes solides d'un antibiotique de type monobactame |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10919887B2 (fr) |
| EP (1) | EP3353175B1 (fr) |
| JP (1) | JP6837480B2 (fr) |
| KR (1) | KR102749337B1 (fr) |
| CN (1) | CN108137573B (fr) |
| AU (1) | AU2016327264B2 (fr) |
| CA (1) | CA2999794C (fr) |
| CL (2) | CL2018000745A1 (fr) |
| CY (1) | CY1123509T1 (fr) |
| DK (1) | DK3353175T3 (fr) |
| EA (2) | EA202092620A1 (fr) |
| ES (1) | ES2817537T3 (fr) |
| HR (1) | HRP20201423T1 (fr) |
| HU (1) | HUE050849T2 (fr) |
| IL (1) | IL258254B (fr) |
| LT (1) | LT3353175T (fr) |
| MA (1) | MA42946B1 (fr) |
| MX (1) | MX377532B (fr) |
| PH (1) | PH12018500653B1 (fr) |
| PL (1) | PL3353175T3 (fr) |
| PT (1) | PT3353175T (fr) |
| RS (1) | RS60805B1 (fr) |
| RU (1) | RU2754180C2 (fr) |
| SI (1) | SI3353175T1 (fr) |
| SM (1) | SMT202000480T1 (fr) |
| WO (1) | WO2017050218A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7235718B2 (ja) * | 2017-08-02 | 2023-03-08 | ノバルティス アーゲー | モノバクタム系抗生物質およびその中間体を製造するための化学的方法 |
| US11760866B2 (en) * | 2017-08-16 | 2023-09-19 | Lg Chem, Ltd. | White pigment comprising ZIF-based powder, polymer resin film and method for changing color of medium using white pigment |
| US20200360349A1 (en) * | 2017-11-10 | 2020-11-19 | Novartis Ag | Administration of monobactam for the treatment of urinary tract infection |
| WO2019144969A1 (fr) | 2018-01-29 | 2019-08-01 | 南京明德新药研发股份有限公司 | Composé b-lactame monocyclique pour traiter une infection bactérienne |
| WO2020125670A1 (fr) | 2018-12-18 | 2020-06-25 | 南京明德新药研发有限公司 | APPLICATION D'UN COMPOSÉ β-LACTAME MONOCYCLIQUE EN PHARMACIE |
| EP4046998B1 (fr) * | 2019-11-22 | 2024-02-28 | Suzhou Erye Pharmaceutical Co., Ltd. | Antibiotiques de beta-lactame monocycliques substitués par un noyau de sulfonylurée |
| CN114828850B (zh) | 2019-12-19 | 2024-08-13 | 深圳嘉科生物科技有限公司 | 化合物在制药中的应用 |
| CN113754651B (zh) | 2020-06-02 | 2023-04-18 | 中国医学科学院医药生物技术研究所 | 一种β-内酰胺化合物、其用途及其制备方法 |
| US12516048B2 (en) | 2020-08-06 | 2026-01-06 | Ningxia Academy Of Agriculture And Forestry Sciences | B-lactam compounds, their preparation and use as antibacterial agents |
| WO2022185240A1 (fr) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Formulation d'un antibiotique monobactame |
| WO2022185241A1 (fr) | 2021-03-04 | 2022-09-09 | Bp Asset Vi, Inc. | Procédé de fabrication d'un antibiotique monobactame |
| CN115304594B (zh) * | 2022-10-12 | 2023-02-14 | 苏州二叶制药有限公司 | 磺酰脲环取代的化合物的盐型及其晶型 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ205240A (en) | 1980-02-07 | 1984-07-31 | Squibb & Sons Inc | Sulphonamide derivatives,being starting materials for producing beta-lactams |
| EP0048953B1 (fr) | 1980-09-29 | 1988-03-09 | E.R. Squibb & Sons, Inc. | Antibiotiques de bêta-lactame |
| US4775670A (en) | 1980-09-29 | 1988-10-04 | E. R. Squibb & Sons, Inc. | 2-oxo-1-azetidinesulfonic acid salts |
| WO1982001873A1 (fr) | 1980-12-05 | 1982-06-10 | Takeda Chemical Industries Ltd | Derives 1-sulfo-2-oxoazetidine et leur procede de preparation |
| US4782147A (en) | 1980-12-05 | 1988-11-01 | Takeda Chemical Industries, Ltd. | 1-sulfo-2-oxoazetidine derivatives and their production |
| CA1262128A (fr) | 1981-08-27 | 1989-10-03 | Christian N. Hubschwerlen | .beta.-lactams |
| IL67451A (en) | 1981-12-25 | 1987-10-20 | Takeda Chemical Industries Ltd | 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them |
| AU564150B2 (en) * | 1982-04-30 | 1987-08-06 | Takeda Chemical Industries Ltd. | 1-sulfo-2-azetidinone derivatives |
| HU189290B (en) | 1982-05-31 | 1986-06-30 | Banyu Pharmaceutical Co Ltd,Jp | Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances |
| EP0096297B1 (fr) | 1982-06-03 | 1988-06-15 | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft | Procédé de préparation de dérivés de 1-sulfo-2-oxoazétidine |
| JPS6153282A (ja) | 1984-08-22 | 1986-03-17 | Banyu Pharmaceut Co Ltd | 単環β−ラクタム誘導体 |
| JPS6153283A (ja) | 1984-08-24 | 1986-03-17 | Banyu Pharmaceut Co Ltd | ２−オキソ−１−アゼチジンスルホン酸誘導体 |
| US4610824A (en) | 1984-10-09 | 1986-09-09 | E. R. Squibb & Sons, Inc. | Hydrazide derivatives of monocyclic beta-lactam antibiotics |
| US5112968A (en) | 1989-07-28 | 1992-05-12 | E. R. Squibb & Sons, Inc. | Monobactam hydrazide derivatives |
| CN102203100B (zh) | 2008-10-31 | 2014-08-27 | 盐野义制药株式会社 | 具有邻苯二酚基团的头孢菌素 |
| JP2012512863A (ja) * | 2008-12-19 | 2012-06-07 | ファイザー・インク | モノカルバム |
| DK2646436T3 (en) | 2010-11-29 | 2015-06-29 | Pfizer | monobactams |
| UY34585A (es) * | 2012-01-24 | 2013-09-02 | Aicuris Gmbh & Co Kg | Compuestos b-lactámicos sustituidos con amidina, su preparación y uso |
| CN103044416A (zh) | 2012-12-17 | 2013-04-17 | 浙江华方药业有限责任公司 | 一种卡芦莫南钠的合成方法 |
| WO2015103583A1 (fr) | 2014-01-06 | 2015-07-09 | President And Fellows Of Harvard College | Monobactames et procédés de synthèse et d'utilisation de ces derniers |
| MX373444B (es) * | 2014-03-24 | 2020-04-30 | Novartis Ag | Compuestos organicos de monobactam para el tratamiento de infecciones bacterianas. |
-
2016
- 2016-09-20 PL PL16848099.4T patent/PL3353175T3/pl unknown
- 2016-09-20 CA CA2999794A patent/CA2999794C/fr active Active
- 2016-09-20 DK DK16848099.4T patent/DK3353175T3/da active
- 2016-09-20 MA MA42946A patent/MA42946B1/fr unknown
- 2016-09-20 SI SI201630906T patent/SI3353175T1/sl unknown
- 2016-09-20 CN CN201680055680.4A patent/CN108137573B/zh active Active
- 2016-09-20 HR HRP20201423TT patent/HRP20201423T1/hr unknown
- 2016-09-20 RU RU2018114480A patent/RU2754180C2/ru active
- 2016-09-20 RS RS20201038A patent/RS60805B1/sr unknown
- 2016-09-20 LT LTEP16848099.4T patent/LT3353175T/lt unknown
- 2016-09-20 WO PCT/CN2016/099482 patent/WO2017050218A1/fr not_active Ceased
- 2016-09-20 ES ES16848099T patent/ES2817537T3/es active Active
- 2016-09-20 JP JP2018515607A patent/JP6837480B2/ja active Active
- 2016-09-20 MX MX2018003592A patent/MX377532B/es active IP Right Grant
- 2016-09-20 AU AU2016327264A patent/AU2016327264B2/en active Active
- 2016-09-20 PT PT168480994T patent/PT3353175T/pt unknown
- 2016-09-20 EA EA202092620A patent/EA202092620A1/ru unknown
- 2016-09-20 EP EP16848099.4A patent/EP3353175B1/fr active Active
- 2016-09-20 SM SM20200480T patent/SMT202000480T1/it unknown
- 2016-09-20 KR KR1020187011354A patent/KR102749337B1/ko active Active
- 2016-09-20 PH PH1/2018/500653A patent/PH12018500653B1/en unknown
- 2016-09-20 EA EA201890771A patent/EA037569B1/ru not_active IP Right Cessation
- 2016-09-20 US US15/762,724 patent/US10919887B2/en active Active
- 2016-09-20 HU HUE16848099A patent/HUE050849T2/hu unknown
-
2018
- 2018-03-20 IL IL258254A patent/IL258254B/en active IP Right Grant
- 2018-03-21 CL CL2018000745A patent/CL2018000745A1/es unknown
-
2019
- 2019-11-20 CL CL2019003324A patent/CL2019003324A1/es unknown
-
2020
- 2020-09-07 CY CY20201100840T patent/CY1123509T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42946A (fr) | Sels et formes solides d'un antibiotique de type monobactame | |
| CL2018001510A1 (es) | Composición farmacéutica que comprende un potente inhibidor de urat1 | |
| PE20141824A1 (es) | Compuestos terapeuticamente activos y sus metodos de uso | |
| BR112019003504A2 (pt) | compostos de amino-pirrolopirimidinona e métodos de uso dos mesmos | |
| EP2727605A4 (fr) | Analogue d'exendine-4 pégylé par du polyéthylène glycol ou un dérivé de celui-ci, son procédé de préparation et composition pharmaceutique pour prévenir ou traiter le diabète, le contenant en tant que principe actif | |
| BRPI0720551A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, e, uso do mesmo, método para o tratamento de câncer, processos para a preparação de uma composição farmacêutica e de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| BR112015022197A8 (pt) | uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia | |
| AR062980A1 (es) | Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida | |
| BR112013032711A2 (pt) | composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase | |
| ZA201802312B (en) | A group of compounds used for the treatment or prevention of hyperuricemia or gout | |
| EP3498264A4 (fr) | Préparation pharmaceutique pour administration orale à vitesse de dissolution contrôlée, la préparation comprenant des pastilles à libération prolongée contenant du chlorhydrate de tamsulosine | |
| MX374628B (es) | Formulacion que comprende un agente hipolipidemico. | |
| MA38854A1 (fr) | Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique | |
| BR112022006608A2 (pt) | Inibidores orais do fator d do complemento | |
| BR112013020456A2 (pt) | nova composição antifúngica | |
| BR122020011180B8 (pt) | formulações injetáveis de compostos de tetraciclina | |
| CL2016002318A1 (es) | Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits. | |
| HRP20200161T1 (hr) | (r)-3-((3s,4s)-3-fluoro-4-(4-hidroksifenil)piperidin-1-il)-1-(4-metilbenzil)pirolidin-2-on i njegovi prolijekovi za liječenje psihijatrijskih poremećaja | |
| MX2017010666A (es) | Acido (2r,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-2-hidroxi-4-[(5-m etiloxazol-2-carbonil)amino]pentanoico. | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| MA54379A (fr) | Nouvelles formes cristallines d'un inhibiteur mcl-1, procédé de préparation associé et compositions pharmaceutiques les contenant | |
| AU2018311521A8 (en) | Process for preparing 1 -(((Z)-(1 -(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-y l)methyl)-1 -sulfoazetidin-3- yl)amino)ethylidene)amino)oxy)cyclopropane carboxylic acid | |
| ATE432262T1 (de) | Pyrazolphenylderivate als ppar-aktivatoren |